Is 'dosing-to-cure' appropriate in the face of antimicrobial resistance?

被引:3
作者
Drlica, K [1 ]
Zhao, XL [1 ]
机构
[1] Publ Hlth Res Inst, Newark, NJ 07103 USA
关键词
mutant selection window; mutant prevention concentration; mutant enrichment;
D O I
10.1097/01.revmedmi.0000131425.36224.59
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In vitro studies have defined antimicrobial concentration ranges within which resistant bacterial mutants are enriched. Each pathogen-antimicrobial combination has a characteristic range called the mutant selection window. Traditional antimicrobial dosing strategies, which are designed to cure disease, tend to place drug concentrations inside selection windows. Removal of resistant mutant subpopulations then relies on the action of host defences rather than antimicrobial treatment. Such strategies will lead increasingly to antimicrobial resistance because immunosuppression is becoming more widespread. Alternative approaches for closing the selection window and for keeping antimicrobial concentrations outside the window are discussed. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 67 条
[51]   What have we learned from pharmacokinetic and pharmacodynamic theories? [J].
Schentag, JJ ;
Gilliland, KK ;
Paladino, JA .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S39-S46
[52]   The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection [J].
Sieradzki, K ;
Roberts, RB ;
Haber, SW ;
Tomasz, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (07) :517-523
[53]   Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria [J].
Sindelar, G ;
Zhao, XL ;
Liew, A ;
Dong, YZ ;
Lu, T ;
Zhou, JF ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3337-3343
[54]   Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy [J].
Thomas, JK ;
Forrest, A ;
Bhavnani, SM ;
Hyatt, JM ;
Cheng, A ;
Ballow, CH ;
Schentag, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :521-527
[55]  
Tillotson G, 2001, Lancet Infect Dis, V1, P145, DOI 10.1016/S1473-3099(01)00090-1
[56]   EXPERIMENTAL ECOLOGICAL-STUDIES ON H-2 PLASMIDS IN THE INTESTINE AND FECES OF THE CALF [J].
TIMONEY, JF ;
LINTON, AH .
JOURNAL OF APPLIED BACTERIOLOGY, 1982, 52 (03) :417-424
[57]   Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: Does antimicrobial choice make a difference? [J].
Toubes, E ;
Singh, K ;
Yin, D ;
Lyu, R ;
Glick, N ;
Russell, L ;
Mohapatra, S ;
Saghal, N ;
Weinstein, RA ;
Trenholme, G .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (06) :724-730
[58]   Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid [J].
Vernon, A ;
Burman, W ;
Benator, D ;
Khan, A ;
Bozeman, L .
LANCET, 1999, 353 (9167) :1843-1847
[59]   PHARMACOKINETIC CONTRIBUTIONS TO POSTANTIBIOTIC EFFECTS - FOCUS ON AMINOGLYCOSIDES [J].
ZHANEL, GG ;
CRAIG, WA .
CLINICAL PHARMACOKINETICS, 1994, 27 (05) :377-392
[60]   Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada [J].
Zhanel, GG ;
Walkty, A ;
Nichol, C ;
Smith, H ;
Noreddin, A ;
Hoban, DJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (01) :63-67